Compare Firy Inc. (FIRY) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Gilead Sciences, Inc. — how do they compare? Firy Inc. trades at $8.37 (market cap $125.48M), while Gilead Sciences, Inc. trades at $134.55 (market cap $163.51B). The key difference: Gilead Sciences, Inc. is far larger — about 1303.1× Firy Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Firy Inc. pays none. Which is the better fit depends on your goals.
| FIRY | GILD | |
|---|---|---|
Market Cap | $125.48M | $163.51B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $155.80 |
52-Week Low | $2.28 | $108.22 |
Enterprise Value | $69.16M | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $8.39, up 4.35% today, with a bullish technical signal from moving averages and RSI near oversold levels. The company recently rebranded from Skillz Inc. and reported Q1 2026 revenue growth but continues significant losses, with a net income margin of -57.48%. Cash flow remains negative, though operating losses have narrowed from prior years.
Outlook is mixed: technical momentum and revenue stabilization offer potential upside, but persistent losses, negative cash flow, and weak profitability metrics pose substantial risks. Analyst consensus is neutral with 60% hold ratings, reflecting cautious optimism amid ongoing financial challenges.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
